Axsome Therapeutics — reboxetine $AXSM
for cataplexy in narcolepsy
Accepted JUL 15 2026.
for cataplexy in narcolepsy
Accepted JUL 15 2026.
Narcolepsy is a chronic neurological disorder characterized by excessive daytime sleepiness and sudden, brief episodes of muscle weakness or paralysis known as cataplexy, often triggered by strong emotions. AXS-12 is an oral drug that works by selectively increasing levels of norepinephrine and modulating dopamine in the brain. By boosting these key signaling chemicals, it could potentially help stabilize muscle control to reduce cataplexy attacks and improve alertness.
This study is a multi-center, double-blind, placebo-controlled, randomized Phase 3 trial to assess the safety and efficacy of AXS-12 in narcoleptic subjects with cataplexy and excessive daytime sleepiness (EDS).
Source: ClinicalTrials.gov